免疫系统
癌症研究
肿瘤微环境
免疫抑制
卵巢癌
生物
卵巢癌
T细胞
免疫学
恶性肿瘤
髓源性抑制细胞
免疫疗法
细胞毒性T细胞
巨噬细胞极化
癌细胞
效应器
免疫耐受
医学
转移
CCL5
细胞培养
癌症
细胞
巨噬细胞
免疫
基因
基诺美
作者
Yue Li,Jin Cheng,Fei Liu,Junjie Yi,Zhefeng Li,Yanheng Yu,Mei Jiang,Xiaoting Zhao,Wentao Yue
标识
DOI:10.1038/s41419-026-08772-4
摘要
High-grade serous ovarian carcinoma (HGSOC) is an aggressive malignancy marked by high recurrence rates, poor prognosis, and limited response to immune checkpoint inhibitors, primarily attributable to its immunologically "cold" tumor microenvironment (TME). To profile the immunological landscape of HGSOC, we conducted single-cell RNA sequencing (scRNA-seq) on 84,065 cells from tumor tissues of eight treatment-naïve patients and one normal ovarian tissue, identifying six major cell clusters and revealing substantial immune cell infiltration. Further analysis of CD8⁺ T cells identified two key subpopulations-precursor and terminally exhausted T cells-and delineated their developmental trajectories. The accumulation of exhausted CD8⁺ T cells (Tex) suggested an immunosuppressive TME. Integrated trajectory inference and high-dimensional weighted gene co-expression network analysis (hdWGCNA) identified CCL3 as a novel hub gene specifically expressed in Tex cells. Communication analysis suggested that Tex cells may interact with M2 macrophages via the CCL3-CCR1 ligand-receptor axis. Functional validation confirmed that: (1) secretomes from Tex cells-but not effector T cells-significantly promoted M2 polarization in both THP-1 and bone marrow-derived macrophages (CD206⁺ THP-1: 83.8% vs. 51.4%, p < 0.001; CD206⁺ BMDM: 72.4% vs. 41.5%, p < 0.001); and (2) recombinant CCL3 acted synergistically with IL-4/IL-10 to further enhance M2 polarization (59.2% vs. 37.7%, p = 0.008). Collectively, our findings unveil a previously unrecognized immunoregulatory axis whereby exhausted CD8⁺ T cells drive immunosuppression via CCL3-CCR1-mediated communication with M2 macrophages, presenting a promising therapeutic target to reverse the immune-cold TME in HGSOC.
科研通智能强力驱动
Strongly Powered by AbleSci AI